Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
22.61
+1.36 (6.40%)
Mar 9, 2026, 4:00 PM EDT - Market closed

Ultragenyx Pharmaceutical Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Market Capitalization
2,1802,2153,8823,9263,2485,732
Upgrade
Market Cap Growth
-44.66%-42.94%-1.13%20.88%-43.33%-37.41%
Upgrade
Enterprise Value
2,6952,6383,9914,3553,1495,183
Upgrade
Last Close Price
22.6123.0042.0747.8246.3384.09
Upgrade
PS Ratio
3.243.296.939.058.9416.31
Upgrade
PB Ratio
--30.3414.8214.269.216.21
Upgrade
P/TBV Ratio
--117.6460.6521.957.67
Upgrade
EV/Sales Ratio
4.003.927.1310.038.6714.75
Upgrade
Debt / Equity Ratio
-17.15-17.153.473.392.570.43
Upgrade
Net Debt / Equity Ratio
-7.05-7.050.630.570.03-0.66
Upgrade
Net Debt / EBITDA Ratio
-1.03-1.03-0.33-0.29-0.021.64
Upgrade
Net Debt / FCF Ratio
-1.09-1.09-0.39-0.30-0.021.47
Upgrade
Asset Turnover
0.440.440.370.290.240.21
Upgrade
Inventory Turnover
17.7117.7119.6322.8234.1535.05
Upgrade
Quick Ratio
2.192.192.142.323.044.33
Upgrade
Current Ratio
2.482.482.382.613.384.72
Upgrade
Return on Equity (ROE)
-608.47%-608.47%-211.75%-193.34%-110.96%-43.72%
Upgrade
Return on Assets (ROA)
-22.03%-22.03%-22.38%-23.42%-26.44%-14.54%
Upgrade
Return on Capital Employed (ROCE)
-46.60%-46.60%-46.20%-47.00%-50.50%-28.50%
Upgrade
Earnings Yield
-26.37%-25.96%-14.66%-15.46%-21.78%-7.92%
Upgrade
FCF Yield
-21.65%-21.31%-10.85%-13.22%-15.29%-7.18%
Upgrade
Buyback Yield / Dilution
-8.95%-8.95%-23.13%-5.13%-3.13%-11.42%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.